Japan Sets Luxturna, Other New Prices While Cutting Selected Fast Growers

Reimbursement Give And Take

Six new drugs including Luxturna will be price-listed in Japan on 30 August, with the Novartis gene therapy set to become the second-most expensive therapeutic product in the country. Behind another round of market expansion-related price cuts for selected drugs, discussions on possible changes to the repricing system are ongoing.

Cortiment, Litfulo, Lytgobi, Empaveli, Oncaspar, ActHIB and Luxturna joined NHI reimbursement list.
Cortiment, Litfulo, Lytgobi, Empaveli, Oncaspar, ActHIB and Luxturna join Japan NHI reimbursement list. • Source: Shutterstock

Japan has set reimbursement prices for six new drugs under its national health insurance (NHI) scheme - including a gene therapy with the second-highest unit price ever for a therapeutic product in the country - along with one-off price cuts for several other drugs that have shown higher than expected growth.

The Ministry of Health, Labour and Welfare (MHLW) announced that the products set to be added to the NHI reimbursement...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Japan

More from Asia